Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06492785
Recruiting Not applicable

Hyaluronic Acid-enriched Transfer Medium in Single Blastocyst Transfer

NCT06492785 · tracked via the Priya Life Science China tracker
Sponsor
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Phase
Not applicable
Started
2024-09-13
Last updated
2025-12-05

Condition(s) studied

Infertility

Investigational drug(s) / intervention(s)

High Hyaluronic Acid concentrations (0.5 mg/ml)Low Hyaluronic Acid concentrations (0.125 mg/ml)

High Hyaluronic Acid concentrations (0.5 mg/ml): Hyaluronic Acid(EmbryoGlue®)

Low Hyaluronic Acid concentrations (0.125 mg/ml): Hyaluronic Acid (G2 medium)

Study summary

The purpose of this study is to compare the live birth rates of high concentration of Hyaluronic Acid (0.5 mg/ml) transfer medium (EmbryoGlue®) to those containing low Hyaluronic Acid concentrations (0.125 mg/ml) (G2 medium) in women undergoing single fresh and frozen blastocyst transfer.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. All cycles with single blastocyst transfer will be considered eligible 2. Both fresh and cryopreserved embryo transfer cycles utilizing autologous oocytes 3. No age restriction will be applied 4. Informed consent was signed Exclusion Criteria: 1. Uterine anatomic anomalies 2. Women with untreated hydrosalpines 3. Once couples have been enrolled in the trial, subsequent cycles will not be incorporated.

Primary outcome measure(s)

  • Live birth rate — Live birth is defined as the birth of at least one live baby after 24 weeks of gestation.
    The primary outcome was Live birth rate per embryo transfer.

Trial sites (1)

FacilityCityRegionStatus
IVF laboratory Xi'an Shaanxi Recruiting

More Northwest Women's and Children's Hospital, Xi'an, Shaanxi trials in China

Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions Recruiting
Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF Recruiting

Other trials for the same condition

Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions Recruiting
Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis Recruiting
Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility Recruiting
Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART) Recruiting
Clinical Value of Saline Infusion Sonohysterography in the Assessment of Cesarean Scar Defects Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06492785 on ClinicalTrials.gov ↗ ← All trials in China